Загрузка...
OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101)
BACKGROUND: Progression-free survival, but not overall survival, was prolonged in the experimental treatment arm with bevacizumab and lomustine (BEV/LOM) compared to the lomustine only control (LOM) arm of randomized EORTC 26101. Secondary outcomes, such as Health-Related Quality of Life (HRQoL), ar...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782536/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.036 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|